APRE - Aprea shares slide 11% after partial clinical hold on myeloid malignancy programs

Aprea Therapeutics (NASDAQ:APRE) shares slide more than 11% post market after the U.S. FDA places partial clinical hold on trials of eprenetapopt in combination with azacitidine in the company's myeloid malignancy programs. There are about 20 patients currently receiving eprenetapopt in combination with azacitidine in the company’s myeloid malignancy programs. Patients who are benefiting from treatment can continue to receive study treatment. However, as part of the clinical hold, no additional patients can be enrolled to these trials until the issue is resolved. Aprea intends to work closely with the FDA to analyze the data, address the specific questions raised, and seek to resolve the partial clinical hold as soon as possible, it said. The partial clinical hold does not apply to the company’s ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial.

For further details see:

Aprea shares slide 11% after partial clinical hold on myeloid malignancy programs